StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM
Stifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Biogen (BIIB) PT Lowered to $290 at Needham & Company
February 4, 2022 6:26 AM
Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage
February 3, 2022 10:37 AM
Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets
February 3, 2022 8:17 AM
Expect Biogen (BIIB) to be Down on Weaker Earnings and Guidance - Needham & Company
February 3, 2022 8:15 AM
Biogen's 2022 forecast well below Street view on Alzheimer's drug uncertainty
February 3, 2022 7:42 AM
Biogen (BIIB) Misses Q4 EPS by 1c, ADUHELM Sales Just $1 Million ; Lowers FY Guidance
February 3, 2022 7:11 AM
